Maribavir trial for CMV prophylaxis discontinued
ViroPharma has announced that it is discontinuing a phase 3 trial of maribavir for prophylaxis against cytomegalovirus (CMV) disease in patients undergoing a liver transplant.
ViroPharma has announced that it is discontinuing a phase 3 trial of maribavir for prophylaxis against cytomegalovirus (CMV) disease in patients undergoing a liver transplant.
The trial is being discontinued based on the results of a phase 3 trial of maribavir in patients undergoing a stem cell transplant; these results were announced in February 2009. In the trial, there was no significant difference between maribavir- and placebo-treated patients on either the primary end point (incidence of CMV disease) or the key secondary end points (initiation of anti-CMV treatment within 6 mo, incidence of graft-vs-host disease, mortality, and CMV disease-free survival).
In February 2007, maribavir was granted orphan drug designation for the prevention of CMV viremia and disease in at-risk populations.
Medicare’s Drug Price Negotiations Could Impact Physician Reimbursement
September 19th 2024When CMS begins negotiations for physician-administered drugs under the Inflation Reduction Act, providers, including those whose services are covered by commercial insurance, could see lowered reimbursement.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
